| Year |
Citation |
Score |
| 2023 |
Zhang B, Gorman J, Kwon YD, Pegu A, Chao CW, Liu T, Asokan M, Bender MF, Bylund T, Damron L, Gollapudi D, Lei P, Li Y, Liu C, Louder MK, et al. Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency. Mabs. 15: 2165390. PMID 36729903 DOI: 10.1080/19420862.2023.2165390 |
0.378 |
|
| 2022 |
Zhang B, Gollapudi D, Gorman J, O'Dell S, Damron LF, McKee K, Asokan M, Yang ES, Pegu A, Lin BC, Chao CW, Chen X, Gama L, Ivleva VB, Law WH, et al. Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life. Scientific Reports. 12: 17876. PMID 36284200 DOI: 10.1038/s41598-022-22435-2 |
0.305 |
|
| 2022 |
Pegu A, Xu L, DeMouth ME, Fabozzi G, March K, Almasri CG, Cully MD, Wang K, Yang ES, Dias J, Fennessey CM, Hataye J, Wei RR, Rao E, Casazza JP, ... ... Asokan M, et al. Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys. Cell Reports. 38: 110199. PMID 34986348 DOI: 10.1016/j.celrep.2021.110199 |
0.441 |
|
| 2021 |
Kwon YD, Asokan M, Gorman J, Zhang B, Liu Q, Louder MK, Lin BC, McKee K, Pegu A, Verardi R, Yang ES, Program VP, Carlton K, Doria-Rose NA, Lusso P, et al. A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention. Mabs. 13: 1946918. PMID 34328065 DOI: 10.1080/19420862.2021.1946918 |
0.303 |
|
| 2020 |
Asokan M, Dias J, Liu C, Maximova A, Ernste K, Pegu A, McKee K, Shi W, Chen X, Almasri C, Promsote W, Ambrozak DR, Gama L, Hu J, Douek DC, et al. Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. Proceedings of the National Academy of Sciences of the United States of America. PMID 32690707 DOI: 10.1073/Pnas.2008236117 |
0.552 |
|
| 2019 |
Krebs SJ, Kwon YD, Schramm CA, Law WH, Donofrio G, Zhou KH, Gift S, Dussupt V, Georgiev IS, Schätzle S, McDaniel JR, Lai YT, Sastry M, Zhang B, Jarosinski MC, ... ... Asokan M, et al. Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. Immunity. PMID 30876875 DOI: 10.1016/J.Immuni.2019.02.008 |
0.526 |
|
| 2019 |
Liu Q, Lai YT, Zhang P, Louder MK, Pegu A, Rawi R, Asokan M, Chen X, Shen CH, Chuang GY, Yang ES, Miao H, Wang Y, Fauci AS, Kwong PD, et al. Improvement of antibody functionality by structure-guided paratope engraftment. Nature Communications. 10: 721. PMID 30760721 DOI: 10.1038/S41467-019-08658-4 |
0.455 |
|
| 2018 |
Xu K, Acharya P, Kong R, Cheng C, Chuang GY, Liu K, Louder MK, O'Dell S, Rawi R, Sastry M, Shen CH, Zhang B, Zhou T, Asokan M, Bailer RT, et al. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nature Medicine. PMID 29867235 DOI: 10.1038/s41591-018-0042-6 |
0.38 |
|
| 2018 |
Kwon YD, Chuang GY, Zhang B, Bailer RT, Doria-Rose NA, Gindin TS, Lin B, Louder MK, McKee K, O'Dell S, Pegu A, Schmidt SD, Asokan M, Chen X, Choe M, et al. Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody. Cell Reports. 22: 1798-1809. PMID 29444432 DOI: 10.1016/J.Celrep.2018.01.023 |
0.429 |
|
| 2018 |
Xu K, Acharya P, Kong R, Cheng C, Chuang GY, Liu K, Louder MK, O'Dell S, Rawi R, Sastry M, Shen CH, Zhang B, Zhou T, Asokan M, Bailer RT, et al. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nature Medicine. 24: 857-867. DOI: 10.2210/Pdb6Cdp/Pdb |
0.479 |
|
| 2017 |
Xu L, Pegu A, Rao E, Doria-Rose N, Beninga J, McKee K, Lord DM, Wei RR, Deng G, Louder M, Schmidt SD, Mankoff Z, Wu L, Asokan M, Beil C, et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science (New York, N.Y.). PMID 28931639 DOI: 10.1126/Science.Aan8630 |
0.509 |
|
| 2016 |
Huang J, Kang BH, Ishida E, Zhou T, Griesman T, Sheng Z, Wu F, Doria-Rose NA, Zhang B, McKee K, O'Dell S, Chuang GY, Druz A, Georgiev IS, Schramm CA, ... ... Asokan M, et al. Identification of a CD4-Binding-Site Antibody to HIV that Evolved Near-Pan Neutralization Breadth. Immunity. 45: 1108-1121. PMID 27851912 DOI: 10.1016/J.Immuni.2016.10.027 |
0.538 |
|
| 2016 |
Joyce MG, Wheatley AK, Thomas PV, Chuang GY, Soto C, Bailer RT, Druz A, Georgiev IS, Gillespie RA, Kanekiyo M, Kong WP, Leung K, Narpala SN, Prabhakaran MS, Yang ES, ... ... Asokan M, et al. Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses. Cell. PMID 27453470 DOI: 10.1016/J.Cell.2016.06.043 |
0.305 |
|
| 2016 |
Kwon YD, Georgiev IS, Ofek G, Zhang B, Asokan M, Bailer RT, Bao A, Caruso W, Chen X, Choe M, Druz A, Ko SY, Louder MK, McKee K, O'Dell S, et al. Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. Journal of Virology. PMID 27053554 DOI: 10.1128/Jvi.03246-15 |
0.428 |
|
| 2015 |
Pegu A, Asokan M, Wu L, Wang K, Hataye J, Casazza JP, Guo X, Shi W, Georgiev I, Zhou T, Chen X, O'Dell S, Todd JP, Kwong PD, Rao SS, et al. Activation and lysis of human CD4 cells latently infected with HIV-1. Nature Communications. 6: 8447. PMID 26485194 DOI: 10.1038/Ncomms9447 |
0.472 |
|
| 2015 |
Doria-Rose NA, Bhiman JN, Roark RS, Schramm CA, Gorman J, Chuang GY, Pancera M, Cale EM, Ernandes MJ, Louder MK, Asokan M, Bailer RT, Druz A, Fraschilla IR, Garrett NJ, et al. A new member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency. Journal of Virology. PMID 26468542 DOI: 10.1128/Jvi.01791-15 |
0.421 |
|
| 2015 |
Asokan M, Rudicell RS, Louder M, McKee K, O'Dell S, Stewart-Jones G, Wang K, Xu L, Chen X, Choe M, Chuang G, Georgiev IS, Joyce MG, Kirys T, Ko S, et al. Bispecific antibodies targeting different epitopes on the HIV-1 envelope exhibit broad and potent neutralization. Journal of Virology. PMID 26446600 DOI: 10.1128/Jvi.02097-15 |
0.512 |
|
| 2014 |
Asokan M, Sachidanandam V, Satish KS, Ranga U. Attenuation of immune activation in an open-label clinical trial for HIV-AIDS using a polyherbal formulation. Virusdisease. 25: 302-13. PMID 25674597 DOI: 10.1007/s13337-014-0218-8 |
0.621 |
|
| 2013 |
Asokan M, Lone IN, Mukthey AB, Siddhartha P, Mariappa G, Kotehal PK, Satish B, Wilson E, Sahayam S, Velayutham G, Perumal R, Baskaran K, Rengarajan D, Muthusamy R, Philip M, et al. Evident stabilization of the clinical profile in HIV/AIDS as evaluated in an open label clinical trial using a polyherbal formulation. The Indian Journal of Medical Research. 137: 1128-44. PMID 23852294 |
0.615 |
|
| 2012 |
Bachu M, Yalla S, Asokan M, Verma A, Neogi U, Sharma S, Murali RV, Mukthey AB, Bhatt R, Chatterjee S, Rajan RE, Cheedarla N, Yadavalli VS, Mahadevan A, Shankar SK, et al. Multiple NF-κB sites in HIV-1 subtype C long terminal repeat confer superior magnitude of transcription and thereby the enhanced viral predominance. The Journal of Biological Chemistry. 287: 44714-35. PMID 23132857 DOI: 10.1074/Jbc.M112.397158 |
0.344 |
|
| Show low-probability matches. |